Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on deals in AMD and dry eye, the U.S. eye care startup will conduct trials on a novel glaucoma treatment, with an option to co-promote.
You may also be interested in...
Otsuka Plans ¥1 Trillion IPO To Expand Beyond Abilify And Soyjoy
Aiming at expanding beyond its blockbuster schizophrenia drug and widely popular personal care products, Japan's fifth-largest drug maker Otsuka Pharmaceutical is reportedly preparing an initial public offering in Tokyo estimated to be valued at over ¥1 trillion ($12 billion) based on calculations of the stock option exercise price, making Otsuka one of the largest Japanese drug makers to go public in a decade
Glaucoma's Changing Of The Guard
Despite a crowded marketplace - with at least seven marketed drugs in at least three different classes -glaucoma remains a disease with a huge unmet need
Otsuka Looks To IPO To Fund Overseas Expansion
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year